How a Split FDA Advisory Panel Voted Six of Seven Peptides Onto the 503A Compounding List Over Its Own Scientists, Rejecting Only Emideltide, and What That Actually Changes for the Market
🎧 Podcast episode for paid subscribers only. Also available on Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Abstract
On July 23 and 24, 2026, FDA’s Pharmacy Compounding Advisory Committee met at White Oak to evaluate seven peptide bulk drug substances for the Section 503A bulks list. FDA career staff recommended against all seven. The committee voted yes on six. Key points:
Day 1 votes: 8 yes, 6 no, 1 abstain for BPC-157, KPV and TB-500, with free base and acetate salt voted separately. MOTS-c came in at 7 yes, 5 no, 2 abstain.
Day 2 votes: Emideltide failed at 6 yes, 7 no, 1 abstain. Epitalon passed at 7 yes, 4 no, 1 abstain. Semax passed at 8 yes, 5 no, 1 abstain.
On Day 1, the eight yes votes were the eight temporary members added to the committee shortly before the meeting. The bloc held until one member broke ranks on Day 2.
The votes are non-binding. Nothing is legal today that was not legal a week ago.
All seven had already come off Category 2 on April 23, 2026, so this was an upside vote, not a re-ban risk.
Every nomination in the packet had been withdrawn by its original nominator. FDA ran the review anyway.
Even a best-case final rule reaches only 503A pharmacies filling patient-specific prescriptions. 503B outsourcing facilities have a separate bulks list and are untouched.
FDA’s 2019 proposed rule on 26 other substances is still unfinished seven years later, which makes the eight to twelve month timeline in the trade press look brave.
The binding constraint after rulemaking is API sourcing, not the list. Section 503A requires bulk substances from an FDA-registered establishment with a valid certificate of analysis, and most peptide API in circulation today does not clear that bar.
A second PCAC meeting is due before the end of February 2027 for Cathelicidin LL-37, GHK-Cu, Dihexa acetate, Melanotan II and PEG-MGF. That slate is materially riskier than this one.
Table of Contents
What actually happened at White Oak
Day two, and the one that failed
A refresher on the bulks list, because it matters more than it sounds
Why peptides fail the four factor test on paper
The nominations were withdrawn and FDA went ahead anyway
The politics that were sitting in the room
Vote math, committee composition, and the conflict of interest fight
What the votes do not do, which is most of what people think they do
Where the money actually moves
The next meeting is the stranger one
What to watch between now and a final rule
What actually happened at White Oak
Two days, seven substances, one advisory committee that had been reconstituted before it walked in the door. FDA’s own scientists, working from briefing documents that ran the standard four factor analysis on each substance, came back with the same answer seven times: do not include. That is a clean sweep. Career staff at the Office of Compounding Quality and Compliance and the clinical review team did not split the difference on a single one.
The committee voted the other way on six.
Day 1 handled BPC-157, KPV, TB-500 and MOTS-c. BPC-157 free base got 8 yes, 6 no, 1 abstain. Then the acetate salt was voted separately and produced the identical tally. KPV, same. TB-500, same. MOTS-c slipped a little at 7 yes, 5 no, 2 abstain, which means somebody who had been comfortable with wound healing decided obesity and osteoporosis indications were a bridge too far. The session ran hours past schedule.
The detail that got buried in most of the coverage is who those eight yes votes belonged to. On the first three substances, the yes bloc consisted entirely of the eight temporary members added to the committee shortly before the meeting. All eight new appointees voted yes. Six pre-existing members voted no. One abstained. On MOTS-c, seven of the eight new appointees voted yes and one abstained, which is the whole explanation for the shift in the tally. That is not a committee deliberating toward a split. That is two groups arriving with conclusions already packed, and one of them being slightly larger.
The tone in the room was not triumphant. One patient representative said out loud that he was voting on something without knowing what the something was, and called it a black box. That is an unusual thing to say into a live webcast right before pressing a button. Another member framed her yes vote around harm reduction, describing a patient who had brought her a research grade vial that turned out to be contaminated with recreational drugs. A physician from Keck pointed at the randomized data on BPC-157, said it suggests no separation from placebo, and warned that an endorsement could be actively harmful. Those three positions are the entire meeting in miniature. Nobody can say what the substance is, the gray market is genuinely dangerous, and the clinical evidence does not support a green light.
